Subgroup analyses in the observational studies indicated that risk of mortality was significantly higher in studies with lower baseline use of vitamin D supplements .
The effects observed for vitamin D3 supplementation remained unchanged when grouped by various characteristics .
However , for vitamin D2 supplementation , increased risks of mortality were observed in studies with lower intervention doses and shorter average intervention periods .
Conclusions Evidence from observational studies indicates inverse associations of circulating 25-hydroxyvitamin D with risks of death due to cardiovascular disease , cancer , and other causes .
Objective To evaluate the extent to which circulating biomarker and supplements of vitamin D are associated with  mortality from cardiovascular , cancer , or other conditions  , under various circumstances .
Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease.
BACKGROUND This post hoc nested case-control analysis of the TNT study was design ed to investigate whether baseline vitamin D level is a significant predictor of cardiovascular risk among statin-treated patients and whether changes in vitamin D after treatment with atorvastatin are associated with improved cardiovascular outcomes . METHODS A total of 10,001 patients with stable coronary heart disease were r and omized to atorvastatin  80 or 10 mg for a median of 4.9 years . This analysis included 1,509 patients ( 497 with a subsequent cardiovascular event and 1,012 without an event ) with vitamin D levels determined at baseline and 1 year . Event rates were analyzed by Cox proportional hazard model by baseline vitamin D levels , with vitamin D as a continuous variable , and with change in vitamin D level as the predictor . RESULTS Vitamin D deficiency ( < 15 ng/mL ) or insufficiency ( 15- < 30 ng/mL ) was present in 108 ( 7.2 % ) of 1,509 and 625 ( 41.4 % ) of 1,509 of patients , whereas 46 ( 3.0 % ) of 1,509 had elevated vitamin D. There was no relationship between baseline vitamin D levels or change in vitamin D levels and cardiovascular events or mortality . Modeling of events with vitamin D as a continuous variable similarly showed no relationship of vitamin D to events . These findings held true after adjustment for seasonal variations in vitamin D and other confounders . CONCLUSION In statin-treated patients with stable coronary heart disease , vitamin D levels did not predict cardiovascular risk . Changes in plasma concentrations of vitamin D after 1 year of treatment made no contribution to the efficacy of atorvastatin therapy
Subgroup analyses in the observational studies indicated that risk of mortality was significantly higher in studies with lower baseline use of vitamin D supplements .
The effects observed for vitamin D3 supplementation remained unchanged when grouped by various characteristics .
However , for vitamin D2 supplementation , increased risks of mortality were observed in studies with lower intervention doses and shorter average intervention periods .
Conclusions Evidence from observational studies indicates inverse associations of circulating 25-hydroxyvitamin D with risks of death due to cardiovascular disease , cancer , and other causes .
Objective To evaluate the extent to which circulating biomarker and supplements of vitamin D are associated with  mortality from cardiovascular , cancer , or other conditions  , under various circumstances .